Lumana Invest

VIVOLTA specializes in the contract development and manufacturing of electrospun medical products, focusing on nanofiber-based solutions that promote the body's natural healing processes. The company has developed advanced electrospinning technologies that enable the production of medical implants, effectively replicating the human extracellular matrix in a reproducible and scalable manner. VIVOLTA's offerings include various methods such as melt electrospinning, wet electrospinning, and emulsion electrospinning, along with specialized modules and tools that enhance the efficiency of electrospinning research. Through these innovations, VIVOLTA supports medical professionals in advancing their medical concepts and improving patient outcomes.

ScoutinScience develops the SiS-AI platform, an artificial intelligence-based technology designed to analyze scientific publications and identify valuable research with significant business potential. This platform aids technology transfer offices (TTOs) and research and development departments by enhancing the impact of research and facilitating the discovery of new technologies. By leveraging AI, ScoutinScience aims to uncover hidden opportunities in scientific data, helping universities and research institutions identify partnership prospects and improve deal flow in the technology transfer process. The company's mission is to convert scientific insights into innovative products and services that contribute positively to society.

ATRO Medical B.V., based in Nijmegen, the Netherlands, focuses on developing innovative solutions for knee joint health through its anatomically shaped meniscus implant, the Trammpolin. This implant is designed to restore the protective function of the meniscus by acting as a joint spacer, thus alleviating pain and improving life quality for patients suffering from osteoarthritis. The company emerged as a spin-out from DSM and Radboudumc, leveraging insights gained from a collaborative initiative that began in 2010, involving various universities and private enterprises with support from the Dutch government. The Trammpolin prosthesis is a synthetic, non-resorbable substitute that mimics the natural meniscus, functioning effectively as a shock absorber by ensuring adequate load distribution within the knee joint.

Neuroplast is a biotechnology company that focuses on developing personalized neuro-regenerative medicine. The company aims to bring qualified autologous stem cell products to the global market, specifically targeting the treatment of spinal cord injuries, amyotrophic lateral sclerosis, and traumatic brain injuries. By isolating, manufacturing, and reinserting patients' own cells, Neuroplast enhances the potential for successful therapies that improve the quality of life for individuals suffering from these conditions. The company recognizes the need for dedicated standards and regulations in the field of neuro-regenerative medicine to ensure effective and safe treatment options.

Sencure is a Dutch start-up established in 2021 that specializes in the development of integrated circuit technology for next-generation healthcare wearable devices. The company focuses on creating ultra-low-power biometric sensing chips that measure electrophysiological parameters of the human body. Sencure's technology supports various applications, including health monitoring devices, disposable medical patches, and health tracking solutions. Its innovations enable healthcare professionals to monitor stress and activity levels, facilitating improved health monitoring in preventative care, clinical research, and overall wellness. By uniting medical device developers and integrated circuit designers, Sencure aims to advance the field of wearable biosensor technology for remote patient monitoring.

Eurekite BV, based in Enschede, the Netherlands, specializes in the manufacture of flexible ceramic materials. Established in May 2015 as a spin-off from the University of Twente, the company focuses on the development and commercialization of its innovative technology, known as Flexiramics®. This technology emerged from the Inorganic Materials Science Group of the MESA + Institute for Nanotechnology, led by Professor Andre ten Elshof. Eurekite combines expertise in formulation chemistry, production technology, and composite development, with its disruptive materials attracting investment from prominent venture capital firms.

VIVOLTA specializes in the contract development and manufacturing of electrospun medical products, focusing on nanofiber-based solutions that promote the body's natural healing processes. The company has developed advanced electrospinning technologies that enable the production of medical implants, effectively replicating the human extracellular matrix in a reproducible and scalable manner. VIVOLTA's offerings include various methods such as melt electrospinning, wet electrospinning, and emulsion electrospinning, along with specialized modules and tools that enhance the efficiency of electrospinning research. Through these innovations, VIVOLTA supports medical professionals in advancing their medical concepts and improving patient outcomes.

LipoCoat is a biotech company that originated as a spin-off from the University of Twente, specializing in innovative coating technology for medical devices. This technology enhances the safety and comfort of devices such as contact lenses, catheters, and implants without relying on antibiotics or toxic substances. The LipoCoat® coatings are bio-inspired, hydrophilic, and multi-purpose, designed to be anti-fouling and sustainable. They render biomaterial surfaces non-thrombogenic and resistant to microbial and protein contamination, thus improving performance and safety for healthcare applications. Over the past three years, LipoCoat has achieved significant recognition, winning 15 awards, competitions, and grants for its advancements in medical technology.

Neuroplast is a biotechnology company that focuses on developing personalized neuro-regenerative medicine. The company aims to bring qualified autologous stem cell products to the global market, specifically targeting the treatment of spinal cord injuries, amyotrophic lateral sclerosis, and traumatic brain injuries. By isolating, manufacturing, and reinserting patients' own cells, Neuroplast enhances the potential for successful therapies that improve the quality of life for individuals suffering from these conditions. The company recognizes the need for dedicated standards and regulations in the field of neuro-regenerative medicine to ensure effective and safe treatment options.